4D Molecular Therapeutics, Inc. Accounts Receivable
4D Molecular Therapeutics, Inc. (FDMT) had Accounts Receivable of $0 as of 2022-12-31, per its 10-K filed 2023-03-15.
Discontinued › Balance Sheet
us-gaap:AccountsReceivableNetCurrent · last filed 2023-03-15
- 2022-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $0.00.
- 2022-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $0.00.
- 2022-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $0.00.
- 2022-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $0.00.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-15 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 |
| 2021-12-31 | $47.00K 10-K · filed 2023-03-15 |
| 2021-09-30 | $791.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $1.22M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $965.00K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $1.49M 10-K · filed 2022-03-28 |
| 2019-12-31 | $978.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |